164 related articles for article (PubMed ID: 38413410)
21. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.
Walter MJ; Shen D; Shao J; Ding L; White BS; Kandoth C; Miller CA; Niu B; McLellan MD; Dees ND; Fulton R; Elliot K; Heath S; Grillot M; Westervelt P; Link DC; DiPersio JF; Mardis E; Ley TJ; Wilson RK; Graubert TA
Leukemia; 2013 Jun; 27(6):1275-82. PubMed ID: 23443460
[TBL] [Abstract][Full Text] [Related]
22. Clonal architecture of secondary acute myeloid leukemia.
Walter MJ; Shen D; Ding L; Shao J; Koboldt DC; Chen K; Larson DE; McLellan MD; Dooling D; Abbott R; Fulton R; Magrini V; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Fan X; Grillot M; Witowski S; Heath S; Frater JL; Eades W; Tomasson M; Westervelt P; DiPersio JF; Link DC; Mardis ER; Ley TJ; Wilson RK; Graubert TA
N Engl J Med; 2012 Mar; 366(12):1090-8. PubMed ID: 22417201
[TBL] [Abstract][Full Text] [Related]
23. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
24. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
25. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
26. [Distribution of abnormal cell clone with deletion of chromosome 20q in marrow cell lineages and apoptosis cells in myelodysplastic syndrome].
Qin L; Wang C; Qin YW; Xie KC; Yan SK; Gao YR; Wang XR; Zhao CX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):551-4. PubMed ID: 18549627
[TBL] [Abstract][Full Text] [Related]
27. Burden of abnormal hematopoietic clone in patients with myelodysplastic syndromes.
Wang HQ; Shao ZH; Shi J; Cao YR; Liu H; Bai J; Tu MF; Xing LM; Cui ZZ; Liu SH; Sun J; Jia HR; Yang TY
Chin Med Sci J; 2006 Jun; 21(2):99-103. PubMed ID: 16845796
[TBL] [Abstract][Full Text] [Related]
28. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
29. Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines.
Bräuninger A; Blau W; Kunze K; Desch AK; Brobeil A; Tur MK; Etschmann B; Günther U; Körholz D; Schliesser G; Käbisch A; Kiehl M; Rummel M; Gattenlöhner S
J Mol Diagn; 2018 May; 20(3):344-354. PubMed ID: 29471115
[TBL] [Abstract][Full Text] [Related]
30. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
Jacoby MA; Duncavage EJ; Chang GS; Miller CA; Shao J; Elliott K; Robinson J; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Pusic I; Welch JS; Link DC; DiPersio JF; Westervelt P; Ley TJ; Graubert TA; Walter MJ
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515031
[TBL] [Abstract][Full Text] [Related]
31. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
[TBL] [Abstract][Full Text] [Related]
32. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
33. [Clonal study on single apoptotic cells in myelodysplastic syndromes].
Li X; Shen WM; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):39-43. PubMed ID: 15946509
[TBL] [Abstract][Full Text] [Related]
34. [Myelodysplastic syndromes: preleukemic syndromes].
Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
[TBL] [Abstract][Full Text] [Related]
35. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
Bernell P; Jacobsson B; Nordgren A; Hast R
Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
[TBL] [Abstract][Full Text] [Related]
36. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
37. Detection of latent subclones with abnormal karyotypes by long-term bone marrow cultures in cases of myelodysplastic syndrome.
Tamura S; Kanamaru A; Kakishita E; Nagai K
Br J Haematol; 1992 Jul; 81(3):353-61. PubMed ID: 1390208
[TBL] [Abstract][Full Text] [Related]
38. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
39. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
